Formed by the proprietary PurcisionTM particle engineering technology, patented large surface area microparticles (LSAMs) of pure drug are suspended at time of use for local delivery via intratumoral, intraperitoneal, instillation, inhalation, and other routes of administration where the particles are retained at the disease site as a depot continuously releasing drug molecules as the particles dissolve over time.


Patented large surface area microparticles (LSAMs) of pure drug are locally delivered directly to the site of disease.

Particles versus Solution

LSAMs become entrapped at the disease site whereas drug in solution leaks out by simple diffusion.

Enabling Technology

The proprietary PurcisionTM technology forms stable LSAMs of pure drug that are suspended in diluent prior to local administration.

Global IP Portfolio

A composition of matter patent protects the regulatory specifications of the LSAMs forming the foundation of an extensive global intellectual property portfolio.